CJC-1295 with DAC: the albumin trick, and what a week-long GHRH signal changes

This is the molecule the name CJC-1295 was coined for. The drug affinity complex is the innovation, and it turns a thirty-minute peptide into a week-long one — which changes what the compound is, not just how often it is injected.

What the DAC is

Established clinical use The drug affinity complex is a maleimidopropionic acid group attached to the peptide. Maleimide reacts with free thiol groups, and the most abundant free thiol in blood is the cysteine-34 residue on serum albumin. So the peptide forms a covalent bond with albumin in circulation and travels as part of it: protected from enzymatic degradation, too large to be filtered by the kidney, and released slowly. The app models the result at a week-long half-life against the unmodified peptide’s thirty minutes.

That is the same strategic idea behind the fatty-acid chains on semaglutide and tirzepatide, executed with a covalent bond rather than a reversible one. The non-DAC page covers the naming confusion this creates: what most vendors sell as "CJC-1295 without DAC" is modified GRF(1-29), a different compound entirely, and the two are dosed nothing alike.

Sustained elevation is a different intervention from a bigger pulse

Growth hormone is normally released in discrete bursts, largely during slow-wave sleep, against a suppressive background of somatostatin. A short-acting GHRH analogue amplifies a burst when the pituitary is ready to produce one. Off-label or community practice A week-long analogue instead holds the releasing signal up continuously, which produces what practitioners call a GH bleed — a raised baseline rather than a taller peak.

Whether that matters is a genuine open question rather than a settled preference. The argument that it does rests on the observation that pulsatility appears to matter to how tissues respond to growth hormone, which is established in physiology; the argument that it does not is that IGF-1 rises either way and IGF-1 is what mediates most of the downstream effect. Nobody has run the trial that would separate them in this population.

Two consequences are less speculative. Receptor desensitisation is a recognised risk with continuous agonism at any receptor, and the app’s own drawbacks list flags faster tachyphylaxis here than with the pulsatile version. And water retention is reported more often, which is what a sustained rather than intermittent GH elevation would predict.

What to measure, and what nobody has measured

IGF-1 is the marker, for the same reason it is on every page in this class: a random serum growth hormone reports where in a pulse the needle went. With a week-long compound the level plateaus over roughly five weeks, so an IGF-1 drawn at two weeks is measuring something still climbing. The IGF-1 page covers why the reference interval is age-dependent. Fasting glucose sits beside it because raising growth hormone reduces insulin sensitivity.

Animal-only or theoretical There is no approved product and no controlled trial of this compound for the uses it is put to. Identity, purity and concentration rest entirely with whoever made the vial, and for a molecule whose entire function depends on an intact reactive maleimide group, manufacturing quality is not a peripheral concern — a degraded batch would behave like the short-acting peptide while being dosed like the long one. This site names no vendor and no testing service.

Anything experienced while using it, and a rising fasting glucose in particular, belongs with a clinician who knows the whole picture rather than being managed against a page.

How long one dose lasts

Try other intervals on the half-life and steady-state calculator, which runs the same function against whatever cadence you type.

The dosing rows the app records

Off-label or community practice Reproduced from the app’s reference so you can see what it holds, not as a recommendation. Which row applies to a particular person, if any, is a clinical decision this page does not make — and rows describing supraphysiological or post-cycle use are filtered out before this table is built, so what you see here is a subset.

What the app monitors alongside it

The panel below is the app’s own monitoring note for CJC-1295 with DAC, verbatim. The analytes in it that have a page here are linked; those pages cover what each one measures, which assay produced it and how to read a trend.

• IGF-1
• HbA1c and fasting glucose

Drawbacks and risks the app records

From the app’s own entry. The first three all follow from the same property — continuous rather than pulsatile signalling — which is the thing the DAC buys and costs.

• Non-pulsatile GH elevation — blunts natural rhythm
• May cause more water retention than pulsatile version
• Tachyphylaxis (desensitization) may develop faster
• Some practitioners prefer pulsatile pattern
• Higher individual dose per injection
• IGF-1 monitoring especially important

Interaction rules that name CJC-1295 with DAC

From the app’s interaction data, filtered so no rule naming a compound this site does not publish appears. Not exhaustive, and not a safety clearance: a combination that is not listed is one nobody has documented here, which is not the same as one that is fine. The combination checker has the rest.

Questions people actually ask

Is this the same as CJC-1295 without DAC?

No, and the naming is the single most common confusion in this family. Without the DAC the compound sold under that name is modified GRF(1-29), with a thirty-minute half-life. This one lasts about a week. They are dosed on completely different schedules.

Does it still need pairing with a secretagogue?

The mechanistic argument for pairing a GHRH analogue with a ghrelin receptor agonist — two receptors, complementary actions on the same pulse — applies here as it does to the short-acting version, and the app’s dosing rows describe it. Whether continuous GHRH signalling plus an intermittent secretagogue behaves like the studied combination is not something anyone has tested.

How long until IGF-1 settles?

About five weeks, at a week-long half-life. Anything drawn before that is measuring a level still accumulating, which is a common reason people conclude a dose is too low and raise it.

Why does it cause more water retention?

Fluid retention is a growth hormone effect, and a compound that raises the signal continuously produces more total exposure than one that raises a pulse. That is the trade the weekly schedule buys.

Where the load-bearing numbers come from

Named rather than linked. Publisher URLs move, and a citation that resolves to a 404 two years from now is worse than one you can search for by name — every entry below is findable from the title and year alone.